Viberzi

Published on Jun 08, 2017

No Description

PRESENTATION OUTLINE

Increased Risk of Pancreatitis

Manufactured by Allergan

Viberzi was initially approved in May 2015

Photo by quimby

Irritable Bowel Syndrome

a condition marked by constipation or diarrhea
Viberzi (Eluxadoline) is approved for diarrhea predominant IBS.
Photo by tranchis

25,000,000

men & women are affected by IBS
Photo by H o l l y.

Pancreatitis is an inflammation of the pancreas.

Photo by PHOTOPHONES

Pancreatitis symptoms

  • Stomach pain
  • Food intolerance
  • Disabling nausea

The FDA received 120 reports of serious pancreatitis and 2 fatal cases

Pancreatitis usually occurs after 2 weeks of taking Viberzi

The deaths occurred after 1 or 2 doses in 48

The FDA recommends that physicians consider alternatives before prescribing Viberzi to patients

Photo by rpongsaj

Untitled Slide

B Fonseca

Haiku Deck Pro User

MORE DECKS BY THIS AUTHOR

Actemra

12 views

Essure

33 views

Abbott

51 views

Neonatal Abstinence Syndrome

48 views

Synchromed II

32 views